Indication
Moderate to severe Pneumonia caused by Pseudomonas aeruginosa, Klebsielia pneumoniae, Streptococcus pneumoniae and other gram negative organisms. Empiric monotherapy for Febrile Neutropenia; Treatment of uncomplicated and complicated Urinary tract infections, including pyelonephritis caused by typical urinary tract pathogens (Escherichia coli, Klebsielia pneumoniae, Proteus mirabilis). Uncomplicated skin and skin structure infections caused by Staphylococcus aureus or Streptococcus pyogenes. It is also used for Intra-abdominal infections with metronidazole and also active against methicillin-susceptible staphylococci and many other gram-negative bacilli.
Dosage & Administration
Children Febrile neutropenia: 50 mg/kg every 8 hours for 7-10 days. Uncomplicated skin/soft tissue infections, pneumonia and complicated/uncomplicated UTI: 50 mg/kg twice daily. Adults Most infections: 1-2 gm every 12 hours for 5-10 days; higher doses or more frequent administration may be required in Pseudomonal infections. Dosing adjustment in renal impairment Adults Recommended maintenance schedule based on creatinine clearance (mL/minute), compared to normal dosing schedule. Hemodialysis Removed by dialysis; administer supplemental dose of 250 mg after each dialysis session. Peritoneal dialysis Removed to a lesser extent than hemodialysis; administer 250 mg every 48 hours. Continuous arteriovenous or venovenous hemofiltration Dose as normal Clcr (eg, >30 mL/minute) Recommended Dosage schedule for Cefa-4TM
Site and Type of Infection | Dose | Frequency | Duration(Days) |
---|---|---|---|
Moderate to Severe Pneumonia due to S.Pneumoniae,P.aeruginosa, K. Pneumoniae, or Enterobacter species | 1-2 g IV | q 12 h | 10 |
Emperic therapy for febrile neutropenic Patients | 2 g IV | q 8 h | 7 |
Mild to Moderate Uncomplicated or complicated UTI, including pyelonephritis, due to E.coli, K. Pneumoniae, or P.mirabilis | 500 mg-1 g | q 12 h | 7-10 |
Severe Uncomplicated or complicated UTI, including pyelonephritis, due to E.coli, K. Pneumoniae, | 2 g IV | q 12 h | 10 |
Moderate to Severe Uncomplicated Skin and Skin Structure Infections due to S.aureus or S.pyogenes | 2 g IV | q 12 h | 10 |
Complicated Intra-abdominal Infections (used in combination with metronidazole) caused by E.coli, virindans group streptococci, P. aeruginosa, K.pneumoniae, Enterobacter species or B.fragilis. | 2 g IV | q 12 h | 7-10 |
Single Dose Vials | Ammount of diluents to be added (ml) |
---|---|
500 mg IV | 5.0 |
500 mg IM | 1.3 |
1 g IV | 10.0 |
1 g IM | 2.4 |
2 g IV | 10.0 |
Precautions
As like other antimicrobials, prolonged use of cefepime may result in overgrowth of nonsusceptible microorganisms. Repeated evaluation of the patient\'s condition is essential.